Human lymphoblastoid cells were transfected with expression vectors containing p53 cDNA mutated at either codon 135 or 246. The cells were subjected to cisplatin treatment or g-radiation and observed for changes in the cell cycle arrest and apoptosis. We found that compared to the parental cell line, cells overexpressing mutant p53 (either 246 val or 135 ser ) exhibited decreased apoptosis in response to g-radiation or cisplatin as measured by: propidium iodide (PI) staining of the cellular DNA (cell cycle analysis) and decrease in PARP (poly ADP-ribose polymerase) cleavage as detected by Western blotting. Interestingly the cells expressing mutant p53(135 ser ) protein were less resistant to cisplatin-induced apoptosis than the p53(246 val )-bearing cell line. A signi®cant decrease in the G1/S arrest assayed by bromodeoxyuridine and PI staining (cell cycle/proliferation assay) was also observed in response to irradiation and cisplatin in cell lines expressing either of the mutant p53 constructs. A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and g-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. No increase in basal levels of Bc12 protein in wild type or mutant p53 expressing cells was observed in response to cisplatin or irradiation. Unexpectedly, following cisplatin treatment we observed an increase in mutant and wild type p53 RNA steady state levels in addition to increased levels of p53 protein. These results suggest that irradiation or cisplatin treatment may not only stabilize wild type p53 protein but also may increase the steady state p53 RNA levels. Finally these results indicate that both irradiation and cisplatin should be used with caution in the treatment of lymphoid tumors bearing mutations of p53.
Human lymphoblastoid cells were transfected with expression vectors containing p53 cDNA mutated at either codon 135 or 246. The cells were subjected to cisplatin treatment or g-radiation and observed for changes in the cell cycle arrest and apoptosis. We found that compared to the parental cell line, cells overexpressing mutant p53 (either 246 val or 135 ser ) exhibited decreased apoptosis in response to g-radiation or cisplatin as measured by: propidium iodide (PI) staining of the cellular DNA (cell cycle analysis) and decrease in PARP (poly ADP-ribose polymerase) cleavage as detected by Western blotting. Interestingly the cells expressing mutant p53(135 ser ) protein were less resistant to cisplatin-induced apoptosis than the p53 (246 val )-bearing cell line. A signi®cant decrease in the G1/S arrest assayed by bromodeoxyuridine and PI staining (cell cycle/proliferation assay) was also observed in response to irradiation and cisplatin in cell lines expressing either of the mutant p53 constructs. A lower basal level and reduced magnitude of protein induction of the cell cycle inhibitor p21/Waf1 was seen both after cisplatin and g-radiation treatment in the mutant p53 expressing lymphoblastoid variant when compared to the wild type p53 parental cell line but induction of the p53 regulator MDM2 was comparable in both. No increase in basal levels of Bc12 protein in wild type or mutant p53 expressing cells was observed in response to cisplatin or irradiation. Unexpectedly, following cisplatin treatment we observed an increase in mutant and wild type p53 RNA steady state levels in addition to increased levels of p53 protein. These results suggest that irradiation or cisplatin treatment may not only stabilize wild type p53 protein but also may increase the steady state p53 RNA levels. Finally these results indicate that both irradiation and cisplatin should be used with caution in the treatment of lymphoid tumors bearing mutations of p53.
Keywords: apoptosis; mutated p53; cisplatin; lymphoblastoid cell lines Introduction P53 is a tumor suppressor gene which is frequently mutated and/or deleted in numerous types of cancer (Hollstein et al., 1991; Nigro et al., 1989) including lymphoproliferative disorders (Farrugia et al., 1994; Gaidano et al., 1991; Li et al., 1995; Sugimoto et al., 1991) . Functional p53 protein is required to either arrest cell progression through the G1/S interphase of the cell cycle and allow for the repair of damaged DNA (Huang et al., 1996; Kastan et al., 1991; Lin et al., 1992) or alternately to promote apoptosis when DNA damage is too extreme (Clarke et al., 1993; Lowe et al., 1993a,b) . Thus expression of wild type p53 has been associated with the sensitivity of a cell to various types of genotoxic stress including radiation (Kuerbitz et al., 1992; Lowe et al., 1993b) and cytotoxic agents (Fujiwara et al., 1994; Lowe et al., 1993a) as well as other growth arrest signals such as hypoxia (Graeber et al., 1994 (Graeber et al., , 1996 ) . Conversely mutations of p53 have been associated with resistance to many of these agents (Fan et al., 1994; Lee and Bernstein, 1993) .
Cisplatin (cis-dichlorodiamminoplatinum II) is frequently used in combination chemotherapy regimens to treat patients with recurrent non-Hodgkin's lymphoma (Rodriguez et al., 1995; Velasquez et al., 1988) . The drug causes platination of DNA (Roberts and Thomson, 1979 ) which leads to inter and intrastrand cross-linking (Eastman, 1985 (Eastman, , 1987 . As a result the rate of DNA synthesis is reduced and often cells become arrested in the G2/M stage of the cell cycle (Ormerod et al., 1994) . Several studies have demonstrated that certain tumor-derived cell lines exposed to high doses of cisplatin die by apoptosis which is preceded by the induction of p53 protein in a dose dependent manner (Allday et al., 1995a; Zhang et al., 1996) . Increased apoptosis in response to cisplatin by gene transfer of wild type p53 in p53-null human lung cancer cell lines (Fujiwara et al., 1994) suggested that p53 is involved in the cell line's sensitivity to the drug. Association between p53 mutations and cisplatin resistance has been also suggested by studies of ovarian carcinoma (Perego et al., 1996) , breast carcinoma (Fan et al., 1995) and other tumor cell lines.
We have derived clonally related lymphoblastoid cell lines that dier from the parental clone only by introduced mutant p53 cDNAs. These clonally derived variants are valuable tools to study the contribution of p53 in the mediation of programmed cell death brought about by various stimuli.
Here we report a direct correlation between cellular chemosensitivity to cisplatin and the intact p53 gene and we show that this sensitivity is mutation speci®c. Moreover we show that the mechanism of this resistance may be related to the induction of mutant as well as wild type p53 by the above agents.
Results

Generation of mutant p53 expressing lymphoblastoid cell lines
We constructed recombinant plasmids containing two dierent mutant p53 cDNAs: cys?ser135 and met?val246 by ligating the mutant p53 cDNAs into pCEP4 expression vectors (Figure 1a) . The constructs were transfected into the lymphoblastoid cell line GM607/pRCCMV and the independent clones expressing high levels of p53 protein as assessed by Western blotting were isolated (Figure 1b) . All of the clones were shown to express similar levels of the p53 protein as indicated in Figure 1b . p53 protein levels were quanti®ed using IPLabGel1.5 software and normalized to the expression of actin. The presence of the recombinant RNA transcript in two independent p53 overexpressing clones transfected with pCEP4/ p53(246 val ) construct con®rmed that mutant protein was indeed overexpressed in those clones (Figure 1c ). Both mutant p53 protein and RNA in the variants were present at levels comparable to the mutant p53 expressed by three independent human diuse large cell lymphoma (DLCL) cell lines, although there was some variability in the protein expression between these DLCL cell lines.
Eects of cisplatin and ionizing radiation on G1/S arrest in mutant p53 overexpressing lymphoblastoid variants Incorporation of the deoxynucleotide analog bromodeoxyuridine (BrdU) into cells allows visualization of cells actively synthesizing DNA and thus permits an accurate measurement of the cell population going through S phase. Combined with the PI staining of the cellular DNA this proliferation/cell cycle assay is an accepted method for quantitation of G1/S arrest p53 mutations and cisplatin sensitivity B Piovesan et al (Peacock et al., 1995) . Both irradiation and cisplatin induced marked G1/S arrest in the parental lymphoblastoid cell line (Figure 2 ). Compared to the control cell line pRCCMV/pCEP4, irradiation of the two independent mutant p53(246 val ) clones assayed 24 h later in four independent experiments resulted in reproducible reductions in G1/S arrest by values ranging from 12 ± 69% (Table 1a) . Similarly, mutant p53(135 ser )c3 showed a 27 ± 81% reduction in radiationinduced G1/S arrest in three independent experiments. Cisplatin treatment resulted in 14 ± 68% reduction in G1/S arrest of the p53(246 val )-expressing cell lines and 6 ± 82% in the p53(135 ser ) variant as compared to the control.
The high value for G1/S arrest observed in the p53(135 ser ) variant in the cisplatin treatment experiment #3 was likely due to a technical error, perhaps an accidental overdose of the chemotoxic drug. Surprisingly our measurements demonstrate the occurrence of substantial G1/S arrest even in the cell lines expressing mutant p53 although, as described earlier, to a lesser extent than in the wild type p53 control. This indicates that wild type p53 protein is still active and its function is impaired but not obliterated by the mutant protein.
As expected the mutant only p53-expressing DLCL cell lines (LY1 and LY8 C3) were found not to undergo G1/S arrest after irradiation with up to 50 Gy unlike the wild type p53-expressing tumor (AML3) and lymphoblastoid (GM607) cell lines (Table 1b) .
Eects of cisplatin and ionizing radiation on apoptosis in mutant p53 overexpressing lymphoblastoid variants When stained with propidium iodide, cells undergoing apoptosis often appear as a subdiploid population, due to the loss of oligonucleotide size DNA fragments by DNase digestion in the early stages of programmed cell death. Others have shown¯ow cytometry of propidium iodide stained cells to be a quantitative method for assessment of apoptosis (Nicoletti et al., 1991; Zinzani et al., 1994) .
Lymphoblastoid mutant p53 transfectants were cultured in the presence of cisplatin for up to 72 h before the assessment of apoptosis. Only data for the 24 h time point are shown here although similar results were obtained at 48 and 72 h. Approximately 4 ± 13 times fewer apoptotic cells were observed in the mutant p53 (246 val ) cell line population and two times less in the Figure 2 G1/S arrest of pRCCMV/pCEP4 cells in response to cisplatin and ionizing radiation. The proliferation/cell cycle assay was performed 24 h after the exposure of the cells to 33 mM cisplatin or 50 Gy of g-radiation. The cells were pulsed with bromodeoxyuridine (BrdU) for 3 h, stained with anti-BrdU antibody and with propidium iodide (a) The summary of G1:S arrest data for mutant p53-expressing lymphoblastoid transfectants and the parental control following 33 mM cisplatin treatment or irraditaion with 50 Gy. (b) The summary of G1:S arrest data for tumor cell lines expressing either mutant only p53 (LY 1, LY8 C3) or wild type (AML 3) as well as wild type p53 bearing LCL (GM 607) following irradiation. G1:S arrest was calculated using the following formula: G1:S ratio of treated cells divided by G1:S ratio of untreated cells. G1 refers to the % of cells present in the G1:G0 and S refers to the % of cells present in the S phase of the cell cycle. These values were obtained from the cell cycle/proliferation assay as described in the legend of Figure 2 p53 mutations and cisplatin sensitivity B Piovesan et al 2341 mutant p53(135 ser ) compared to the wild type p53 control cell line pRCCMV/pCEP4 ( Figure 3 ). As expected the clonally related Bcl2 overexpressing lymphoblastoid cell line (bcl2/pCEP4) and the human DLCL cell line exhibit even lower levels of apoptosis upon cisplatin treatment. Irradiation shown by others to induce apoptosis through p53 dependent pathway (Lowe et al., 1993b) , similarly resulted in lower levels of apoptosis in the mutant p53 or Bcl2 expressing cell lines as well as the DLCL cell line. Compared to the wild type control the population of apoptotic cells after irradiation was approximately four times less for p53 (246 val ) and 2 ± 3 times less for p53(135 ser ) expressing cell lines as well as over 20 times less for either Bcl2-overexpressing variant or DLCL cell line. Other DLCL cell lines showed similar behavior to that of Figure 3 Decrease in cisplatin-induced apoptosis in mutant p53 overexpressing cell lines measured by cell cycle assay. Control (pRCCMV/pCEP4) cell line, four independent clones of mutant p53-transfected GM607/pRCCMV cells, a DLCL cell line (LY8C3) and Bc12-overexpressing control (bcl2/pCEP4) after being passaged once in B27 supplement-containing media, were incubated with 33 mM cisplatin for 24 h or treated with 50 Gy of radiation. Cell cycle was assayed 24 h later by propidium iodide (PI) staining of the DNA and by the¯ow cytometric analysis of 10 000 cells. The per cent of cells present in the subdiploid population is displayed above each histogram p53 mutations and cisplatin sensitivity B Piovesan et al LY8 c3 although there was noticeable variability between cell cycle pro®les of the DLCL cell lines in response to cisplatin or radiation (data not shown). The DLCL cell lines in general displayed lower basal and induced levels of apoptosis than the mutant p53 variants which we generated likely due to the fact that the former express only mutant p53 protein (i.e. no wild type) in conjunction with other genetic abnormalities. The lymphoblastoid mutant p53 variants on the other hand, also express wild type endogenous p53 Figure 4 Decreased cleavage of PARP (poly ADP-ribose polymerase) in response to cisplatin in lymphoblastoid cell lines expressing mutant p53. Western blot analysis using the monoclonal anti-PARP antibody (C2-10) showed PARP cleavage followed over a 24 ± 48 h period after treatment with 33 mM cisplatin. Parental cells (pRCCMV/pCEP4) were compared to two clones carrying the mutant p53(246 val )/pCEP4 construct (a) and one clone expressing the mutant p53(135 ser )/pCEP4 construct (b). A lymphoblastoid cell line overexpressing Bcl2 (bcl2/pCEP4) (c) and two diuse large cell lymphoma cell lines known to carry p53 mutations (LY8C3 and LY1) were compared to the parental lymphoblastoid cell line (d). Expression of actin was used as a loading control. Cellular equivalent of 10 5 cells was loaded in each lane which likely contributes to the albeit reduced, apoptosis. The cell cycle assay showed similar results when cells had been passaged in 15% BCS-containing media (data not shown) or B-27 supplement containing media prior to the delivery of the apoptosis triggering stimulus, however more reproducible results were obtained using B-27 supplement.
Induction of PARP cleavage by cisplatin in mutant p53 overexpressing lymphoblastoid transfectants and in the lymphoma cell lines PARP inactivation by proteolytic cleavage is an early event in apoptosis that is easily detected by Western blotting (Casciola-Rosen et al., 1996; Gu et al., 1995) . In wildtype p53 expressing cell lines the 85 kDa product of that cleavage was apparent prior to exposure to cisplatin probably indicating basal levels of apoptosis (Figure 4a and b) . The intensity of the 85 kDa band started to increase 8 h after cisplatin treatment and was accompanied by a decrease in the intensity of the band representing uncleaved 115 kDa protein. As expected this cleavage was markedly reduced in the clonally related variant overexpressing Bcl2 protein (bcl2/pCEP4; Figure 4c ). In all of the mutant p53 expressing transfectants the cleavage product band was considerably less intense than that seen in the parental pRCCMV/pCEP4 clone and only appeared around 24 h post-treatment. No comparisons of the degree of PARP cleavage can be made between the p53(246 val ) and p53(135 ser ) clones as they were tested in separate experiments and hence were compared only to the wild type control.
The background levels of PARP cleavage product were also less intense in the DLCL cell lines than in the lymphoblastoid cell line (Figure 4d ). In addition there was considerably less cleavage product at 24 h in the DLCL cell lines than in the control lymphoblastoid cell line. Similar results were observed in two independent experiments. These results were also seen after irradiation of the mutant p53(246 val ) expressing lymphoblastoid transfectants with 50 Gy (data not shown).
Alterations in the levels of p53, Bcl2, p21/Waf1 and MDM2 proteins in the mutant p53 transfectants following treatment with cisplatin
As expected g-radiation treatment of the wildtype lymphoblastoid control resulted in an increase of the p53 over 24 h (Figure 5a ). Unexpectedly the levels of p53 protein increased in the mutant p53 transfectants as well as in the DLCL cell lines (Figure 5a ). No change in the levels of Bcl2 protein was seen in any of the lymphoblastoid cell lines assessed over 24 h (Figure 5a ).
Cisplatin treatment also resulted in an increase in p53 protein in both dierent mutant (Figure 5b (Figure 5d ). Similarly to the results with irradiation, no change in Bcl2 protein levels was observed. All experiments were repeated twice with similar results.
P21/Waf1 and MDM2 were assessed in AML3, pRCCMV/pCEP4, and pRCCMV/p53(246 val )c10 25 h after irradiation (Figure 6a ) or after exposure to cisplatin for 25 h (Figure 6b ). In the two cell lines without mutant p53 (AML3 and pRCCMV/pCEP4) Figure 6 Induction of Waf1/p21 and MDM2 proteins in the lymphoblastoid cell lines in response to treatment with 50 Gy of gradiation (a) or 33 mM cisplatin (b). Western blot analysis was performed over a 25 h period following treatment. The cells bearing mutant p53(246 val )/pCEP4 construct were compared to the vector-bearing parental cells (pRCCMV/pCEP4). A wild-type p53 expressing leukemia cell line (AML3) was used as a positive control for p53-dependent Waf1/p21 and MDM2 induction. Cellular equivalent of 10 5 cells was loaded in each lane. Coomassie brilliant blue-stained total protein lysates showed below the p21 and MDM2 bands were used as loading controls in the calculations of the protein levels summarized in Table 2 p53 mutations and cisplatin sensitivity B Piovesan et al increases in both p21/Waf1 and MDM2 were seen. MDM2 protein levels were shown by others to increase after irradiation (Vaziri et al., 1997) . Although p21/ Waf1 and MDM2 protein levels increased in the pRCCMV/p53(246 val )c10 cell line, the basal levels of p21/waf1 and MDM2 were decreased in pRCCMV/ p53(246 val )c10 and the absolute level of increase of p21/ Waf1 protein was lower in this cell line as compared to the parental line. A quantitative analysis of these data, is shown normalized to protein levels in Table 2 .
Induction of mutant p53 RNA after exposure to cisplatin Because irradiation and cisplatin resulted in an increase in the p53 protein levels in not only the control wt p53 cell line but also unexpectedly in the mutant p53 transfectants ( Figure 5 ) we wished to determine whether any changes occurred at the p53 mRNA level. Surprisingly, we found that cisplatin treatment induced a tenfold increase in the levels of transfected mutant p53 RNA within the 24 h time course as visualized by the increase in the intensity of the lower, 1.8 kb band of transgenic RNA in the mutant p53 bearing cell clones ( Figure 7 and Table 3 ). A small increase in wild type p53 levels was seen although its quanti®cation was dicult as it was partially masked by the very strong signal of the mutant p53 RNA band.
To determine whether the increase in steady state p53 mRNA levels was due to RNA stabilization, p53 mRNA levels were assessed at multiple time points in the presence of Actinomycin D after exposure to cisplatin (Figure 8a ) and compared to the RNA levels in the presence of Actinomycin D only (Figure 8b) . No signi®cant increases in the half lives of the wild type or transgenic mutant p53 mRNAs were demonstrated (Figure 8c ). These data suggest that increased p53 transcription of both wild type or mutant p53 may contribute to the increase in the steady state of mRNA levels after exposure to cisplatin.
Discussion
Cisplatin is an important cytotoxic drug used in the treatment of many malignancies including non-Hodgkin's B cell lymphoma. Cisplatin treatment induces apoptosis and there is evidence that this apoptosis may be dependent on a functional p53 tumour suppressor gene (Allday et al., 1995a; Fujiwara et al., 1994) . Recently Perego et al., (1996) isolated cisplatin resistant mutants of an ovarian carcinoma cell line that were found to have acquired a mutation of p53. These mutants however may have gained other genetic aberrations which could have contributed to cisplatin resistance in addition to the p53 mutation. The issue of whether cisplatin can induce apoptosis in cancers with p53 mutations thus remains an important unresolved question with clinical relevance.
To determine the importance of p53 mutations in cisplatin resistance we generated clonally derived variants of a lymphoblastoid cell line that diered only by introduced mutant p53 cDNAs. We introduced one of two dierent mutations, both of which were previously shown to transform rat embryo ®broblasts in a dominant negative manner (Slingerland and Benchimol, 1991) . Our data shows that these mutated p53 proteins were expressed in our clones and that these mutations were indeed functional, although the endogenous p53 protein was still being expressed and at least partially functional. That is, we demonstrated that as expected there was a reduction in the G1/S arrest after irradiation in all mutant cell lines tested. Others have shown that G1/S arrest after irradiation is dependent upon intact wild type p53 (Kuerbitz et al., 1992) . In addition we demonstrated that clones expressing these mutant p53 genes underwent less apoptosis than the parental clone in response to irradiation and that there was a diminished induction of p21/Waf1 after irradiation in clones expressing mutant p53. Summary of the changes in the levels of MDM-2 and p21 proteins following 33 mM cisplatin treatment or irradiation with 50 Gy in a wild type p53-expressing leukemia cell line AML3 and pRCCMV/pCEP4 and pRCCMV/p53(246 val ) cell lines. Cells were lysed at indicated time intervals after treatment. The numbers represent intensity of the bands measured using IPLabG3l 1.5 software, where the levels of MDM2 and p21 were normalized to the respective total protein levels measured by Coomasie blue staining of the gel (as shown in Figure 6 ) Figure 7 Increase in the level of mutant p53 RNA following treatment with cisplatin. Cells were incubated after addition of 33 mM cisplatin for 8 or 24 h at which time total RNA was isolated. Ten mg of RNA was electrophoresed. P53 was detected using a 1.3 kb p53 cDNA fragment originally isolated from LY8C3 cell line and the 1.0 kb cDNA fragment speci®c for human b-action gene was used to detect actin p53 mutations and cisplatin sensitivity B Piovesan et al
Having thus established the validity of our experimental system we then assessed the response of the various clones to cisplatin exposure. We found that whereas the parental cell line underwent apoptosis in response to cisplatin, there was signi®cantly less apoptosis in the variant lines engineered to express either p53 mutation. Apoptosis, however, was not abrogated likely because these cell lines still express endogenous wild type p53 alongside the transgenic mutant protein. To be convinced of the correctness of this observation we measured apoptosis using two dierent methodologies: propidium iodide (PI) staining for detection of a subdiploid population and cleavage of PARP. Concordant results were obtained using both techniques although the clones expressing p53(246 val ) mutant were more resistant to cisplatin than the clones expressing the p53(135 ser ) as measured by PI staining assay. These results clearly demonstrate that apoptosis induced by cisplatin is induced through a p53 pathway and that this apoptosis may be abrogated to some degree in cells harboring mutations of p53. We can thus add genotoxic stress induced by cisplatin to the increasing list of stimuli that induce apoptosis through a p53 pathway (Fujiwara et al., 1994; Graeber et al., 1994 Graeber et al., , 1996 Kuerbitz et al., 1992; Lowe et al., 1993a,b) .
These results also suggest that dierent mutations may interfere with cisplatin activation of the p53 pathway to dierent degrees. That is, less resistance to apoptosis was reproducibly seen in the two clones containing the p53(135 ser ) mutation. This mutation was also less transforming when coexpressed in rat embryo ®broblasts with an activated ras cDNA (Slingerland and Benchimol, 1991) . Others have shown that dierent p53 mutations may have dierent eects on the p53 pathway. For example dierent p53 mutations had varying eects on a colon carcinoma cell line's ability to undergo G1/S arrest (Pocard et al., 1996) .
An unexpected observation resulting from our investigations was that p53 protein levels increased after irradiation and cisplatin treatment in the mutant lymphoblastoid clones as well as in the wild type clone. Similar results were observed following DNA-damaging insults using two DLCL cell lines expressing only mutated p53. When we assessed the mRNA levels of two of the mutant p53(246 val ) clones after treatment with cisplatin, we found that the drug induced signi®cant increases in the transfected mutant p53 mRNA and to a lesser extent in the endogenous wild type p53. Moreover we found that the half lives of the mutant and endogenous wild type p53 RNAs did not Figure 8 Assessment of the half life of transgenic and endogenous wild type p53 RNA. PRCCMV/p53(246 val )c10 cells were exposed to cisplatin in the presence of the transcriptional inhibitor Actinomycin D. Cells were incubated for 4 h in 33 mM cisplatin followed by 5 mg/ml Actinomycin D (a) or were incubated in Actinomycin D only (b). RNA was extracted and assessed by Northern blot after indicated time points. RNA levels were calculated by densitometric analysis using IPLabGel 1.5 software, were normalized to the respective actin levels and were plotted for transgenic p53 RNA as shown in (c), or endogenous p53 RNA as shown in (d) signi®cantly change after exposure to cisplatin, implying that increased transcription through the endogenous p53 promoter as well as the transgenic CMV promoter may have been playing a role in the increased steady state mRNA levels seen after cisplatin treatment. Increased p53 protein levels in response to genotoxic stress have been shown to be mostly related to post translational mechanisms (Kastan et al., 1991; Maltzman and Czyzyk, 1984) although enhanced transcription has also been suggested (Kastan et al., 1991; Kondo et al., 1996; Voelkerding et al., 1995) . Further experiments to better understand the role of transcriptional mechanism in the regulation of wild type and mutant p53 RNA are underway. However these experiments suggest that the eects of mutant p53 could be exaggerated by increasing mutant p53 levels in response to genotoxic stress such as cisplatin.
We found that p21/Waf1 protein levels increased in both the wild type and mutant p53 expressing lymphoblastoid clones after irradiation and cisplatin treatment but the basal level of p21/Waf1 expression and the absolute stimulated level were less than those seen in the wild type control. Previously cisplatin has been reported to induce p21/Waf1 protein within 6 h in human foreskin ®broblasts (Hawkins et al., 1996) . MDM2 was also induced with both treatments although the kinetics of that induction varied with the type of genotoxic stress. Minimal, if any dierences were observed in MDM2 induction between the wild type and mutant p53 expressing lymphoblastoid clones although again less basal levels of MDM1 protein expression were seen in the mutant p53 expressing lymphoblastoid clone. The ®nding that p21 induction was impaired to a greater extent in our mutant p53 expressing variant while MDM2 induction is not, could be explained by the fact that these genes mediate opposite actions and thus could be regulated at dierent levels. Similarly, dierential regulation of those two p53-activated genes was suggested by UVirradiation experiments in primary rat and mouse cells (Wu and Levine, 1997) . Induction of these p53-dependent proteins in our mutant p53-bearing variant could be explained by the endogenously expressed wild type p53.
Contrary to a report of a p53-driven control of expression of the bcl2 gene in murine leukemia cell line (Miyashita et al., 1994) we did not observe suppression of Bcl2 protein associated with increased p53 levels following DNA damaging treatments. Neither do we see increased expression levels of Bcl2 in the cells bearing mutant p53. Since another study reported no change in the levels of Bcl2 in lymphoblastoid cell lines exposed to cisplatin (Allday et al., 1995a) these discrepancies are clearly modelspeci®c. It is possible that the use of temperatureinducible p53 construct in the murine system triggers dierent response pathways than the DNA damaging treatments.
In conclusion we have shown that cisplatin induces G1/S arrest and apoptosis in human lymphoblastoid cell lines and that these eects are dependent on a functional p53 tumour suppressor gene. Lymphoblastoid cell lines expressing both mutant and wild type p53 protein undergo less G1/S arrest and apoptosis than clonally related wild type p53 cell lines. Moreover we provide evidence that cisplatin may enhance the levels of mutant and wild type p53 protein possibly at least to some extent via a mechanism of increased p53 transcription. These ®ndings should be further investigated as they suggest that cisplatin treatment of lymphoid tumors bearing certain mutations of p53 may not only be ineective but also potentially detrimental.
Materials and methods
Cell lines and culture conditions
Human lymphoblastoid cell line GM607 was obtained from Dr L Rubin (University of Toronto, Canada). It is a nontransformed B cell line which has been immortalized with Epstein ± Barr virus (Allday et al., 1995b) . GM607/ pRCCMV behaves the same as GM607 and is used as a control cell line in these assays. It was generated as a vector only control for other types of experiments and mutant p53 constructs were transfected into it. Human diuse large cell lymphoma cell lines used in the study included: OCI LY1, LY2 and LY8 C3 (Tweeddale et al., 1987) All cells were cultured in RPMI1640 (Wisent, Que Canada) supplemented with 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 15% bovine calf serum (Wisent) at 378C and 5% CO 2 . GM607/pRCCMV was grown in the above media but with addition of 750 mg/ ml of G418 (GIBCO ± BRL, Gaithersburg, MD, USA) while the mutant p53 variants and pRCCMV/pCEP4 and bcl2/ pCEP4 controls were cultured with both 750 mg/ml G418 and 150 mg/ml hygromycin (GIBCO ± BRL). For some of the apoptosis assays (wherever indicated) the 15% bovine calf serum contained in the growth media was replaced by B-27 supplement (GIBCO ± BRL).
Plasmids and constructs
pCEP4 (Invitrogen Corp., San Diego, CA, USA) is a CMV promoter based and hygromycin resistance conferring shuttle vector. It was used to express mutant P53 (Met?Val246 or Cys?Ser135) cDNAs (Slingerland and Benchimol, 1991; Slingerland et al., 1993) . The 1.8 kb cDNAs were blunt-ended and ligated into PvuII site of the pCEP4 vector. pRCCMV (Invitrogen Corp.), a CMV promoter-driven shuttle vector carrying G418 (geneticin sulphate) resistance gene was used for the overexpression of bcl2 cDNA to create an apoptosis resistant control (bcl2/pCEP4). The 0.9 kb bcl2 cDNA was digested out of an EcoRI site in a pB4 plasmid, blunt-ended and subcloned into pRCCMV which had been digested with NotI and then blunt-ended. All ligations were performed using T4 DNA ligase (GIBCO ± BRL). The ligated products were electroporated into XL1-Blue Escherichia coli and clear colonies were screened by Southern blotting. Large quantities of the plasmids were produced using standard plasmid preparation techniques using pZ523 TM spin columns (5prime?3prime, Inc., Boulder, CO, USA).
Establishment of mutant p53 variants
GM607/pRCCMV cells were electroporated with either pCEP4 vector or one of: pCEP4/p53(246 val ) or pCEP4/ p53(135 ser ) constructs using the Gene Pulser system (Bio Rad, Hercules, CA, USA). 3610 7 cells in 0.75 ml of PBS were mixed with 50 ± 100 mg of plasmid DNA in 100 ml of PBS, pulsed at 700 V and 25 mF and incubated at 5% CO 2 and 378C for 48 h in non-selective media. Then the cells were plated out at 10 4 , 10 3 and 10 2 cells per well in 96 well plates in media with the addition of hygromycin at 750 mg/ml and grown for 2 ± 3 weeks. Colonies were expanded o the plates where less than 30% of the wells contained growing cells, and were then screened by Western blot. Bcl2/pCEP4 control cell line was generated in similar manner but bcl2 cDNA was subcloned into a pRCCMV plasmid and electroporated into the parental cell line GM607.
Drug treatment
Cells growing in log phase were subcultured at 3610 5 cells/ ml and 24 h later cisplatin (Bristol Laboratories, Montreal, Que) was added to a ®nal concentration of 33 mM. For cell cycle and proliferation assays 5 ± 8610 6 cells were incubated for 24 h after the addition of cisplatin. For Western blot analysis 10 6 cells were lysed either before or at speci®c time points after the addition of cisplatin. Actinomycin D (Sigma-Aldrich, Canada) dissolved at 5 mg/ml in ethanol was used as a transcriptional inhibitor to assess the half life of p53 mRNA transcript.
Immunoblotting
Cells were lysed in a lysis buer composed of 10 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA (pH 8), 1% Triton X-100, 1 mM PMSF and 0.23 m/ml aprotinin by incubation on ice for 15 ± 30 min. Debris was sedimented by centrifugation at 14 000 r.p.m. at 48C for 10 min and 10 ml of each supernatant was added to 5 ml of a sample buer containing 0.188 M Tris (pH 6.8), 6% SDS, 30% glycerol, 15% 2-mercaptoethanol and 0.015% of bromophenol blue. Proteins were resolved at 150 V for 1.5 h on 4 ± 12% polyacrylamide gradient gels (Novex, San Diego, CA) and electrophoretically transferred to PVDF membrane (Millipore, Mississauga, ON). Membranes were blocked for 2 h at room temperature in a buer composed of 50 mM Tris, 140 mM NaCl and 0.1% Tween-20 and containing 4% BSA. They were probed for 2 h with the primary and then for 1 h with the secondary antibody diluted in the above buer but containing 1% BSA.
The primary antibodies used: mouse anti-human p53 (pAB1801, PharMingen, San Diego, CA), hamster antihuman Bcl2 (6C8, PharMingen), mouse anti-human p21/ Waf1 (Calbiochem, Cambridge, MA), mouse anti-human MDM2 (Ab-1, Calbiochem), mouse anti-human PARP (C2-10, obtained from Dr G Poirier, U of Laval, Que) and mouse anti-actin (Amersham, Arlington Heights, IL). The secondary antibodies used: sheep anti-mouse HRP (1 : 5000, Amersham) and rabbit anti-hamster HRP (1 : 5000, Amersham). Immunoreactive material was then visualized by enhanced chemiluminescence (Amersham).
Northern blotting
Total RNA was isolated using TRIZOL 1 (GIBCO ± BRL) reagent according to the manufacturer's instructions. 10 mg of RNA was electrophoresed under denaturing conditions following standard protocols and transferred to a Zeta-probe nylon membrane, UV-crosslinked, prehybridized and hybridized to an appropriate p32 alabeled probe. All technical procedures followed were provided by the manufacturer of Zeta-probe. Probes used included: 1.0 kb cDNA fragment speci®c for human bactin gene and 1.3 kb BamHI/HindIII p53 cDNA fragment originally isolated from LY8C3 cell line and cloned into pCEP4 vector.
Cell cycle analysis
5610
6 cells were washed with PBS buer (5.4 mM KCl, 2.8 mM Na 2 HPO 4 , 2.9 mM and 0.3 M NaCl, pH 7.3) and ®xed in 80% ethanol on ice for 1 h. They were centrifuged at 3000 r.p.m., washed with PBS and then with a propidium iodide staining buer (PIB: PBS buer with the addition of 0.12% Triton X-100 and 0.12 mM EDTA). The cells were resuspended in RNAseA/PIB (50 ± 100 mg/ ml) and incubated at 378C for 45 min. PI solution (5 mg/ ml propidium iodide dissolved in PIB) was added at 50 mg/ ml and the reactions were incubated at room temperature in the dark for at least 1 h. The analysis was performed on the day of the assay using a¯ow cytometer (Becton Dickinson, Mountain View, CA).
Cell cycle/proliferation assay
The protocol described earlier (Peacock et al., 1995) was followed with small changes. Cells were incubated for 24 h after the treatment and were pulsed for 3 h with 18 mg/ml of bromodeoxyuridine.
Assessment of the p53 mRNA half life PRCCMV/p53(246 val )c10 cells growing in log phase at 5610 5 cells per ml, were subdivided into three¯asks. Cisplatin was added to a concentration of 33 mM to twō asks. At this time point an aliquot of 5610 6 cells was removed from the untreated¯ask for total RNA extraction. After 4 h at 378C, 5610 6 cells were taken from the treated¯asks for RNA preparation. At that point the transcriptional inhibitor, actinomycin D, was added to a ®nal concentration of 5 mg/ml to a cisplatin treated culture and to the untreated culture. Cells were then further incubated at 378C and aliquots were taken for RNA extraction at 2, 6, 9 and 19 h. 10 mg of RNA was electophoresed and Northern blots were prepared as described previously. Densitometric analysis using IPLabGel 1.5 software was used to normalize the p53 signals with respect to actin.
